NORGINE PHARMA UK LIMITED
Get an alert when NORGINE PHARMA UK LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2027-02-04 (in 9mo)
Last made up 2026-01-21
Watchouts
None on the register
Cash
—
Latest balance sheet
Net assets
-£7M
Equity attributable
Employees
0
Average over period
Profit before tax
-£7M
Period ending 2024-12-31
Net assets
1-year trend · vs Consumer Discretionary median
Accounts
1-year trend · latest reflected 2024-12-31
| Metric | Trend | 2024-12-31 |
|---|---|---|
| Turnover | — | |
| Operating profit | -£5,225,044 | |
| Profit before tax | -£7,345,517 | |
| Net profit | -£7,345,517 | |
| Cash | — | |
| Total assets less current liabilities | £41,777,957 | |
| Net assets | -£7,345,516 | |
| Equity | -£7,345,516 | |
| Average employees | 0 | |
| Wages | — | |
| Directors' remuneration | £0 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Year-on-year
Latest filed period vs the prior one
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2024-12-31 |
|---|---|---|
| Return on capital employed | -12.5% | |
| Current ratio | 0.00x | |
| Interest cover | -2.09x |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Company meets its day-to day working capital requirements through the Group treasury function. On 2 May 2024, the Group completed a refinancing of its €650 million term loan... Based on the Directors' formal assessment, which covers the period to 30 September 2026, the Directors are satisfied that the Group is a going concern and these financial statements have therefore been prepared on a Going Concern basis.”
Significant events
- “On 18 March 2024 the Company entered into an exclusive licensing transaction with Fennec Pharmaceuticals, Inc. ("Fennec") to develop and commercialise PEDMARQSI (sodium thiosulfate injection) in Europe, Australia and New Zealand. On signing of the agreement the Group paid Fennec an upfront payment of €40m.”
- “In December 2024, the Group also received a positive National Institute for Health and Care Excellence (NICE) opinion for PEDMARQSI® (sodium thiosulfate injection) in the UK.”
- “On 15 March 2024 Spinnaker Debtco Limited, the Company's direct parent, advanced an amount of €40m to Fennec on behalf of the company in satisfaction of the upfront payment due. This constituted a loan from Spinnaker Debtco Limited to the Company and was redenominated into sterling as a loan principal of £34.2m.”
- “In January 2025, the Company entered into an exclusive licensing agreement with X4 Pharmaceuticals, Inc. to commercialise Mavorixafor in Europe, Australia, and New Zealand. On signing the agreement the Group made a €28.5m upfront payment, funded by a draw down on the Groups Revolving Credit Facility (RCF), and paid on the Company's behalf by Spinnaker Debtco Limited.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 1 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| BARRETO MARTINIANO, Saulo | Director | 2024-01-22 | Dec 1972 | Brazilian |
| SHARMA, Sandeep | Director | 2024-09-30 | Mar 1970 | British |
| VAN DER KAMP, Hilde Johanna | Director | 2024-12-04 | Mar 1975 | Dutch |
Show 1 resigned officer
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BATH, Christopher William | Director | 2024-01-22 | 2024-09-30 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Spinnaker Debtco Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2024-01-22 | Active |
Filing timeline
Last 12 of 12 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-02-02 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-10-04 | AA | accounts | Accounts with accounts type full | |
| 2025-03-04 | CH01 | officers | Change person director company with change date | |
| 2025-02-03 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2025-02-03 | AD01 | address | Change registered office address company with date old address new address | |
| 2025-01-21 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-12-19 | AP01 | officers | Appoint person director company with name date | |
| 2024-10-09 | AP01 | officers | Appoint person director company with name date | |
| 2024-10-09 | TM01 | officers | Termination director company with name termination date | |
| 2024-07-02 | CH01 | officers | Change person director company with change date | |
| 2024-01-22 | AA01 | accounts | Change account reference date company current shortened | |
| 2024-01-22 | NEWINC | incorporation | Incorporation company |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.